| 4B05: Preclinical Characterization Of Azd3839, A Novel Clinical Ca Bace1 Inhibitor For The Treatment Of Alzheimer Disease reference: Discovery of AZD3839, a potent and selective BACE1 clinical candidate for the treatment of Alzheimers Disease., Jeppsson F, Eketjall S, Janson J, Karlstrom S, Gustavsson S, Olsson LL, Radesater AC, Ploeger B, Cebers G, Kolmodin K, Swahn BM, von Berg S, Bueters T, Falting J, J Biol Chem. 2012 Oct 9. PMID: 23048024 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).